Subcutaneous · GLP-1 / GIP dual
RAY1225
11 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
11
Active
8
Recruiting
3
Completed
3
Sites
6
Countries
1
Endpoints
45
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
6
Phase 2
2
Phase 3
3
Trials by status
Not yet recruiting
3
Recruiting
3
Active, not recruiting
2
Completed
3
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
19
Glycemic / diabetes
14
Weight & body composition
12
Most-measured metrics
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
1
HbA1c <7.0% achievementGlycemic
1
HbA1c <6.5% achievementGlycemic
1
HbA1c <5.7% achievementGlycemic
1
Fasting glucose, changeGlycemic
1
≥5% weight-loss respondersWeight
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
11 of 11